CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net income	$ 37,858	$ 109,695
Adjustments to reconcile net income to net cash provided by operating activities:
Deferred income tax	6,860	19,736
Depreciation and amortization	3,501	3,460
Stock-based compensation	954	451
Amortization of debt discount and issuance costs	377	2,211
Changes in fair values of equity and long-term investments, net	9,411	(54,673)
Loss on extinguishment of debt	20,662	0
Other	280	8
Changes in operating assets and liabilities:
Receivables from collaborative arrangements	17,196	4,957
Prepaid expenses	1,345	243
Other assets, current	99	328
Accounts payable	198	(52)
Accrued personnel-related expenses and other accrued liabilities	2,116	227
Accrued interest payable	(2,755)	(2,484)
Net cash provided by operating activities	98,102	84,107
Cash flows from investing activities
Purchases of equity and long term investments	(56,217)	(26,394)
Purchases of equity investments managed by ISP Fund LP	(2,015)	(112,587)
Sale of equity investments managed by ISP Fund LP	24,281	2,387
Purchase and sales of other investments managed by ISP Fund LP, net	(132,266)	110,200
Purchases of property and equipment	(9)	0
Cash acquired through the consolidation of Entasis Therapeutics Holdings, Inc.	23,070	0
Net cash used in investing activities	(143,156)	(26,394)
Cash flows from financing activities
Distributions to noncontrolling interest	(6,507)	(21,285)
Repurchase of shares to satisfy tax withholding	(46)	(25)
Proceeds from issuances of common stock, net	260	0
Payment for repurchase of convertible subordinated notes due 2023	(165,131)	0
Purchases of capped call options associated with convertible senior notes due 2028	(21,037)	0
Proceeds from issuance of convertible senior notes due 2028, net of issuance costs	252,792	0
Net cash provided by (used in) financing activities	60,331	(21,310)
Net increase (decrease) in cash and cash equivalents	15,277	36,403
Cash and cash equivalents at beginning of period	201,525	246,487
Cash and cash equivalents at end of period	216,802	282,890
Supplemental disclosure of cash flow information
Cash paid for interest	5,411	4,967
Supplemental disclosure of non-cash investing and financing activities
Right-of-use asset obtained through the consolidation of Entasis Therapeutics Holdings, Inc	3,289	0
ASU 2020-06
Supplemental disclosure of non-cash investing and financing activities
Adoption of ASU 2020-06	$ 28,123	$ 0